These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
5. Expression of the oncogenic NPM-ALK chimeric protein in human lymphoid T-cells inhibits drug-induced, but not Fas-induced apoptosis. Greenland C; Touriol C; Chevillard G; Morris SW; Bai R; Duyster J; Delsol G; Allouche M Oncogene; 2001 Nov; 20(50):7386-97. PubMed ID: 11704868 [TBL] [Abstract][Full Text] [Related]
6. Role of the nucleophosmin (NPM) portion of the non-Hodgkin's lymphoma-associated NPM-anaplastic lymphoma kinase fusion protein in oncogenesis. Bischof D; Pulford K; Mason DY; Morris SW Mol Cell Biol; 1997 Apr; 17(4):2312-25. PubMed ID: 9121481 [TBL] [Abstract][Full Text] [Related]
7. Nucleophosmin-anaplastic lymphoma kinase of anaplastic large-cell lymphoma recruits, activates, and uses pp60c-src to mediate its mitogenicity. Cussac D; Greenland C; Roche S; Bai RY; Duyster J; Morris SW; Delsol G; Allouche M; Payrastre B Blood; 2004 Feb; 103(4):1464-71. PubMed ID: 14563642 [TBL] [Abstract][Full Text] [Related]
8. NPM/ALK downregulates p27Kip1 in a PI-3K-dependent manner. Slupianek A; Skorski T Exp Hematol; 2004 Dec; 32(12):1265-71. PubMed ID: 15588951 [TBL] [Abstract][Full Text] [Related]
9. Role of phosphatidylinositol 3-kinase-Akt pathway in nucleophosmin/anaplastic lymphoma kinase-mediated lymphomagenesis. Slupianek A; Nieborowska-Skorska M; Hoser G; Morrione A; Majewski M; Xue L; Morris SW; Wasik MA; Skorski T Cancer Res; 2001 Mar; 61(5):2194-9. PubMed ID: 11280786 [TBL] [Abstract][Full Text] [Related]
10. NPM/ALK binds and phosphorylates the RNA/DNA-binding protein PSF in anaplastic large-cell lymphoma. Galietta A; Gunby RH; Redaelli S; Stano P; Carniti C; Bachi A; Tucker PW; Tartari CJ; Huang CJ; Colombo E; Pulford K; Puttini M; Piazza RG; Ruchatz H; Villa A; Donella-Deana A; Marin O; Perrotti D; Gambacorti-Passerini C Blood; 2007 Oct; 110(7):2600-9. PubMed ID: 17537995 [TBL] [Abstract][Full Text] [Related]
11. The tyrosine phosphatase Shp2 interacts with NPM-ALK and regulates anaplastic lymphoma cell growth and migration. Voena C; Conte C; Ambrogio C; Boeri Erba E; Boccalatte F; Mohammed S; Jensen ON; Palestro G; Inghirami G; Chiarle R Cancer Res; 2007 May; 67(9):4278-86. PubMed ID: 17483340 [TBL] [Abstract][Full Text] [Related]
12. Oncogenic tyrosine kinase NPM/ALK induces activation of the rapamycin-sensitive mTOR signaling pathway. Marzec M; Kasprzycka M; Liu X; El-Salem M; Halasa K; Raghunath PN; Bucki R; Wlodarski P; Wasik MA Oncogene; 2007 Aug; 26(38):5606-14. PubMed ID: 17353907 [TBL] [Abstract][Full Text] [Related]
13. p130Cas mediates the transforming properties of the anaplastic lymphoma kinase. Ambrogio C; Voena C; Manazza AD; Piva R; Riera L; Barberis L; Costa C; Tarone G; Defilippi P; Hirsch E; Boeri Erba E; Mohammed S; Jensen ON; Palestro G; Inghirami G; Chiarle R Blood; 2005 Dec; 106(12):3907-16. PubMed ID: 16105984 [TBL] [Abstract][Full Text] [Related]
14. A ligand-inducible epidermal growth factor receptor/anaplastic lymphoma kinase chimera promotes mitogenesis and transforming properties in 3T3 cells. Piccinini G; Bacchiocchi R; Serresi M; Vivani C; Rossetti S; Gennaretti C; Carbonari D; Fazioli F J Biol Chem; 2002 Jun; 277(25):22231-9. PubMed ID: 11919185 [TBL] [Abstract][Full Text] [Related]
15. Nucleophosmin-anaplastic lymphoma kinase (NPM-ALK), a novel Hsp90-client tyrosine kinase: down-regulation of NPM-ALK expression and tyrosine phosphorylation in ALK(+) CD30(+) lymphoma cells by the Hsp90 antagonist 17-allylamino,17-demethoxygeldanamycin. Bonvini P; Gastaldi T; Falini B; Rosolen A Cancer Res; 2002 Mar; 62(5):1559-66. PubMed ID: 11888936 [TBL] [Abstract][Full Text] [Related]
16. Bcl-XL down-regulation suppresses the tumorigenic potential of NPM/ALK in vitro and in vivo. Coluccia AM; Perego S; Cleris L; Gunby RH; Passoni L; Marchesi E; Formelli F; Gambacorti-Passerini C Blood; 2004 Apr; 103(7):2787-94. PubMed ID: 14656879 [TBL] [Abstract][Full Text] [Related]
17. Structural basis for the recognition of nucleophosmin-anaplastic lymphoma kinase oncoprotein by the phosphotyrosine binding domain of Suc1-associated neurotrophic factor-induced tyrosine-phosphorylated target-2. Koshiba S; Li H; Motoda Y; Tomizawa T; Kasai T; Tochio N; Yabuki T; Harada T; Watanabe S; Tanaka A; Shirouzu M; Kigawa T; Yamamoto T; Yokoyama S J Struct Funct Genomics; 2010 Jun; 11(2):125-41. PubMed ID: 20454865 [TBL] [Abstract][Full Text] [Related]
18. A "liaison dangereuse" between AUF1/hnRNPD and the oncogenic tyrosine kinase NPM-ALK. Fawal M; Armstrong F; Ollier S; Dupont H; Touriol C; Monsarrat B; Delsol G; Payrastre B; Morello D Blood; 2006 Oct; 108(8):2780-8. PubMed ID: 16835382 [TBL] [Abstract][Full Text] [Related]
19. Identification of multiple SNT-binding sites on NPM-ALK oncoprotein and their involvement in cell transformation. Chikamori M; Fujimoto J; Tokai-Nishizumi N; Yamamoto T Oncogene; 2007 May; 26(20):2950-4. PubMed ID: 17086210 [TBL] [Abstract][Full Text] [Related]
20. Involvement of Grb2 adaptor protein in nucleophosmin-anaplastic lymphoma kinase (NPM-ALK)-mediated signaling and anaplastic large cell lymphoma growth. Riera L; Lasorsa E; Ambrogio C; Surrenti N; Voena C; Chiarle R J Biol Chem; 2010 Aug; 285(34):26441-50. PubMed ID: 20554525 [TBL] [Abstract][Full Text] [Related] [Next] [New Search]